Published in Lancet on February 24, 2007
Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents (ORAR III) | NCT00552669
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation | NCT02176265
BES, EES, and ZES-R in Real World Practice (CHOICE) | NCT01397175
The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol (2011) 3.71
Coronary revascularization trends in the United States, 2001-2008. JAMA (2011) 2.81
Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA (2008) 2.47
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
The long-term effect of coronary stenting on epicardial and microvascular endothelial function. Circ Cardiovasc Interv (2012) 2.03
Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med (2011) 1.84
Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation (2008) 1.68
Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. Comp Med (2010) 1.61
A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest (2014) 1.52
Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes (2011) 1.51
Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv (2008) 1.49
Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J (2015) 1.29
Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2008) 1.18
Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovasc Interv (2011) 1.16
Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation (2008) 1.10
Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J (2010) 1.01
Ultra-thin strut cobalt chromium bare metal stent usage in a complex real-world setting. (SOLSTICE registry). Neth Heart J (2015) 0.99
Very late thrombosis of a drug-eluting stent after discontinuation of dual antiplatelet therapy in a patient treated with both drug-eluting and bare-metal stents. Korean Circ J (2009) 0.99
Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Control Release (2008) 0.95
Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area: from the Tokyo CCU network registered cohort. Heart Vessels (2016) 0.95
Second- and third-generation drug-eluting coronary stents: progress and safety. Herz (2011) 0.93
Stent evaluation with optical coherence tomography. Yonsei Med J (2013) 0.92
Late stent thrombosis, endothelialisation and drug-eluting stents. Neth Heart J (2009) 0.91
Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord (2010) 0.90
Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev (2009) 0.90
Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart (2007) 0.90
Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels (2012) 0.90
Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol (2010) 0.90
Changes in the Practice of Coronary Revascularization between 2006 and 2010 in the Republic of Korea. Yonsei Med J (2015) 0.89
Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol (2013) 0.89
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart (2014) 0.88
Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol (2011) 0.88
Nanomedicine for the reduction of the thrombogenicity of stent coatings. Int J Nanomedicine (2010) 0.88
Stent thrombosis: incidence, predictors and new technologies. Thrombosis (2012) 0.87
Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. Heart Vessels (2015) 0.87
Surface modification of a polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells. Biointerphases (2013) 0.86
Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era. Heart Vessels (2011) 0.86
Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol (2012) 0.86
Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol (2013) 0.85
The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J (2010) 0.85
Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.84
Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart (2007) 0.84
Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol (2011) 0.84
Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv (2015) 0.83
Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation. Int J Cardiovasc Imaging (2011) 0.83
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up. Clin Res Cardiol (2007) 0.83
Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol (2012) 0.83
Coronary stent healing, endothelialisation and the role of co-medication. Neth Heart J (2007) 0.83
Second generation drug-eluting stents: a review of the everolimus-eluting platform. Clin Med Insights Cardiol (2013) 0.83
Optimal revascularization for complex coronary artery disease. Nat Rev Cardiol (2013) 0.83
Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents. Yonsei Med J (2012) 0.83
Long-term (≥2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results. Int J Cardiovasc Imaging (2010) 0.82
Are drug-eluting stents safe in the long term? CMAJ (2008) 0.82
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging (2011) 0.82
A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. Indian Heart J (2012) 0.81
Percutaneous coronary intervention for unprotected left main disease in very high risk patients: safety of drug-eluting stents. Heart Vessels (2010) 0.81
Pathological perspective of drug-eluting stent thrombosis. Thrombosis (2012) 0.81
Comparison of Two Different Strategies of Intravascular Ultrasound Guidance during Percutaneous Coronary Intervention; Routine versus Selective. Korean Circ J (2013) 0.81
Association of localized hypersensitivity and in-stent neoatherosclerosis with the very late drug-eluting stent thrombosis. PLoS One (2014) 0.81
Clinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Arch Med Sci (2014) 0.81
Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circ Cardiovasc Interv (2010) 0.81
Multifaceted prospects of nanocomposites for cardiovascular grafts and stents. Int J Nanomedicine (2015) 0.81
Enhanced endothelialization on surface modified poly(L-lactic acid) substrates. Tissue Eng Part A (2010) 0.81
Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clin Res Cardiol (2010) 0.80
Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting. Vasc Health Risk Manag (2011) 0.80
Short-term consequences of angiographically-confirmed coronary stent thrombosis. PLoS One (2013) 0.80
Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. J Exp Med (2014) 0.80
Everolimus-eluting stents in interventional cardiology. Vasc Health Risk Manag (2012) 0.80
The invasive assessment of coronary atherosclerosis and stents using optical coherence tomography: a clinical update. Heart Asia (2013) 0.80
Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. PLoS One (2013) 0.80
Nitinol-based nanotubular coatings for the modulation of human vascular cell function. Nano Lett (2014) 0.79
The relationship between re-endothelialization and endothelial function after DES implantation: comparison between paclitaxcel eluting stent and zotarolims eluting stent. Catheter Cardiovasc Interv (2014) 0.79
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. Biologics (2013) 0.79
Everolimus-eluting stents improve vascular response in a diabetic animal model. Circ Cardiovasc Interv (2014) 0.79
The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use. Clin Res Cardiol (2009) 0.79
Comparison of drug-eluting stents in acute myocardial infarction patients with chronic kidney disease. Korean J Intern Med (2012) 0.79
Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study. PLoS One (2014) 0.79
Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. Clin Res Cardiol (2013) 0.79
Correlation of angiographic late loss with neointimal coverage of drug-eluting stent struts on follow-up optical coherence tomography. Int J Cardiovasc Imaging (2011) 0.79
Quality of life (QOL) evaluation after acute coronary syndrome with simultaneous clopidogrel treatment. Arch Med Sci (2013) 0.79
Neoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis. World J Cardiol (2015) 0.79
Optimization of Drug Delivery by Drug-Eluting Stents. PLoS One (2015) 0.78
Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol (2013) 0.78
Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol (2013) 0.78
Prevention of Collagen-Induced Platelet Binding and Activation by Thermosensitive Nanoparticles. AAPS J (2015) 0.78
Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol Res (2014) 0.78
Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. Heart Vessels (2011) 0.78
Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial. Int J Cardiovasc Imaging (2013) 0.78
Very Late Stent Thrombosis of Sirolimus-eluting Stent 59 Months After Implantation: A First Report from The Middle-East and Review of Literature. Heart Views (2011) 0.78
Role of Intravascular Ultrasound in Patients with Acute Myocardial Infarction. Korean Circ J (2015) 0.78
Nanotechnology in interventional cardiology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.78
STENTING STRATEGY AND FOLLOW-UP RESULTS OF MULTI-CENTER REGISTRY IN FUKUSHIMA CITY FOR LEFT MAIN CORONARY ARTERY DISEASE: BARE METAL STENT VERSUS DRUG-ELUTING STENT. Fukushima J Med Sci (2015) 0.78
Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching. Yonsei Med J (2017) 0.78
Favorable Outcomes after Implantation of Biodegradable Polymer Coated Sirolimus-Eluting Stents in Diabetic Population: Results from INDOLIMUS-G Diabetic Registry. Int J Vasc Med (2015) 0.78
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ (2002) 7.26
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med (2007) 6.17
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94
Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ (2010) 5.68
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med (2009) 5.26
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16
Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94
Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med (2012) 4.87
High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med (2015) 4.68
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med (2014) 4.37
Soluble CD40 ligand in acute coronary syndromes. N Engl J Med (2003) 4.06
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol (2005) 4.05
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol (2004) 3.87
Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol (2007) 3.82
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60
All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ (2011) 3.51
Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation (2006) 3.50
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med (2013) 3.46
Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation (2007) 3.40
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol (2007) 3.28
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol (2006) 3.16
Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med (2002) 3.16
Concern Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J (2009) 3.14
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med (2005) 3.08
Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol (2006) 3.07
Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06
Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01
Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation (2003) 2.97
Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ (2007) 2.93
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91
Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90
Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ (2010) 2.88
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J (2006) 2.87
Stent thrombosis. J Am Coll Cardiol (2010) 2.86
Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation (2007) 2.85
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85